CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive

CRISPR Therapeutics AG

2025-Q3 EPS reported -$5.12 revenue$2,646,000

Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).
CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.
CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.
CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.
SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.